Incyte Biosciences International Sàrl

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Incyte Biosciences International Sàrl sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Incyte Biosciences International Sàrl: 7 sponsored US clinical trials, none currently recruiting.

Incyte Biosciences International Sàrl sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Head and Neck Cancer, with 1 trials.

Upper-quartile sponsor footprint

Incyte Biosciences International Sàrl sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05287113
COMPLETED Phase 1

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

NCT03538028
TERMINATED Phase 1

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

NCT03277352
COMPLETED Phase 1

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

NCT03241173
COMPLETED Phase 1

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

NCT03126110
COMPLETED Phase 1

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

NCT02923349
COMPLETED Phase 1

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

NCT02697591

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 1

Therapeutic Areas

Head and Neck Cancer 1

How the Incyte Biosciences International Sàrl early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 5 completed (71%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Head and Neck Cancer (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Incyte Biosciences International Sàrl: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Incyte Biosciences International Sàrl sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Incyte Biosciences International Sàrl3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Incyte Biosciences International Sàrl sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Incyte Biosciences International Sàrl sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Incyte Biosciences International Sàrl page

7 registered trials is a research-attention snapshot, not an endorsement of Incyte Biosciences International Sàrl or any single study.

  • None of Incyte Biosciences International Sàrl's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Head and Neck Cancer is the condition Incyte Biosciences International Sàrl studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Head and Neck Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Incyte Biosciences International Sàrl pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.